Insmed

Investigator-Initiated Research

Helping scientists investigate the unanswered

We will consider providing financial support and/or product supply for novel research proposals that answer important scientific and medical questions in our areas of interest. Grant recipients have the right to publish the results of the study and maintain full control over the research project objectives, design, conduct, data analysis, and interpretation.

Contact us with any questions about requirements and procedures.

Submit a request for grant support.

Areas of interest

Amikacin Liposome Inhalation Suspension and Pulmonary Infections

  • NTM pulmonary disease in different populations [such as autoimmune disease/COPD comorbidities and other populations]
  • Biomarkers and/or imaging findings for NTM diagnosis, comorbidities, disease progression, and treatment decisions
  • Studies in populations with both comorbidities of MACLD and bronchiectasis *
  • Adverse event/medication adherence management
  • Evaluation of factors affecting patient initiation and acceptance of NTM treatment
  • Explore an AI-guided approach to diagnosis and disease management using imaging and other tools

*Any studies noted requiring brensocatib will be considered but held in regions until approved by the relevant health authority.

Bronchiectasis and Other Neutrophil-Related Disorders

Mechanistic studies in relevant disease state models and translational research

  • Neutrophil serine protease (NSP) biomarkers, and other inflammatory biomarkers, of disease severity/burden/progression in patients with inflammatory diseases
  • Pre-clinical science, translational studies, and laboratory research evaluating the biology of dysregulated neutrophilic inflammation; mechanisms of disease; and effect of DPP1 inhibition in bronchiectasis, hidradenitis suppurativa (HS), and across subpopulations (including but not limited to Asian populations)

Bronchiectasis disease state 

  • Assessment of bronchiectasis epidemiology and patient journey to understand potential underdiagnosis/misdiagnosis of bronchiectasis in patients with comorbidities (e.g., COPD, asthma), identifying predictors of bronchiectasis in these cohorts and how comorbidities may affect timely diagnosis and long-term outcomes.  
  • Drivers of bronchiectasis disease progression and long-term severe outcomes  

Brensocatib treatment and treatment outcomes  

  • Understanding of the real-world use and impact of brensocatib* on progression of disease and in understudied bronchiectasis populations (including but not limited to patients with NTM, minority populations, smokers, patients at high risk of exacerbations) 
  • Novel combinations with brensocatib*

New disease areas

  • Evaluate brensocatib* in patients with neutrophil-driven disease including Dermatology / Immunology / Rheumatology / Pulmonology [excluding studies focused on COPD, Asthma, HS, rheumatoid arthritis (RA), Inflammatory Bowel Disease (IBD)]  

Key Research Collaboration Scientific Area of Interest

  • Collaboration to explore AI-guided approaches to bronchiectasis diagnosis, identification, follow-up, etc. 

 

*Any Studies noted requiring brensocatib will be considered but held in regions until approved by the relevant health authority.